R Eastell1, A Rogers, X Ni, J H Krege. 1. NIHR Bone Biomedical Research Unit, Centre for Biomedical Research, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK. r.eastell@sheffield.ac.uk
Abstract
UNLABELLED: Raloxifene decreases PINP into the lower half of the premenopausal reference interval; alendronate decreases PINP more, with approximately 60% of alendronate-treated women having PINP concentrations below the lower limit of the premenopausal reference interval. INTRODUCTION: The purpose of this study was to evaluate the distribution of serum procollagen type I N-terminal propeptide (PINP) concentrations in women with postmenopausal osteoporosis prior to treatment and after treatment with eitherraloxifene or alendronatefor 12 or more months. METHODS: Included were data from 1,323 postmenopausal women aged 45 to 87 years, collected at baseline or after treatment with eitheralendronate 10 mg/day or raloxifene 60 mg/day. These patients had participated in one of four clinical trials in which intact PINP was measured by radioimmunoassay (Orion Diagnostica). A premenopausal reference interval from 16.0 to 75.8 μg/L was determined from 68 premenopausal, non-pregnant women. RESULTS: Most postmenopausal osteoporotic patients prior to treatment had PINP values in the upper half of the premenopausal reference interval at baseline (70%). After ≥ 12 months of therapy, most patients who received raloxifene had PINP concentrations in the lower half of the premenopausal reference interval (58%), whereas among those who received alendronate, around 60% of patients had PINP concentrations below the lower limit of the premenopausal reference interval. CONCLUSION: PINP may be useful for assessing differences in bone turnover response to different types of anti-resorptive therapy.
RCT Entities:
UNLABELLED: Raloxifene decreases PINP into the lower half of the premenopausal reference interval; alendronate decreases PINP more, with approximately 60% of alendronate-treated women having PINP concentrations below the lower limit of the premenopausal reference interval. INTRODUCTION: The purpose of this study was to evaluate the distribution of serum procollagen type I N-terminal propeptide (PINP) concentrations in women with postmenopausal osteoporosis prior to treatment and after treatment with either raloxifene or alendronate for 12 or more months. METHODS: Included were data from 1,323 postmenopausal women aged 45 to 87 years, collected at baseline or after treatment with either alendronate 10 mg/day or raloxifene 60 mg/day. These patients had participated in one of four clinical trials in which intact PINP was measured by radioimmunoassay (Orion Diagnostica). A premenopausal reference interval from 16.0 to 75.8 μg/L was determined from 68 premenopausal, non-pregnant women. RESULTS: Most postmenopausal osteoporoticpatients prior to treatment had PINP values in the upper half of the premenopausal reference interval at baseline (70%). After ≥ 12 months of therapy, most patients who received raloxifene had PINP concentrations in the lower half of the premenopausal reference interval (58%), whereas among those who received alendronate, around 60% of patients had PINP concentrations below the lower limit of the premenopausal reference interval. CONCLUSION: PINP may be useful for assessing differences in bone turnover response to different types of anti-resorptive therapy.
Authors: Marc C Hochberg; Susan Greenspan; Richard D Wasnich; Paul Miller; Desmond E Thompson; Philip D Ross Journal: J Clin Endocrinol Metab Date: 2002-04 Impact factor: 5.958
Authors: B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings Journal: JAMA Date: 1999-08-18 Impact factor: 56.272